Combined Treatment for Inflammatory Non-Metastatic Breast Cancer
Author Information
Author(s): B. Chevallier, P. Bastit, Y. Graic, J.F. Menard, J.P. Dauce, J.P. Julien, B. Clavier, A. Kunlin, J. D'Anjou
Primary Institution: Centre H. Becquerel, Rouen, France
Hypothesis
Can a combined modality approach improve response rates and survival in patients with inflammatory non-metastatic breast cancer?
Conclusion
The study suggests that while response rates improved with intensive chemotherapy, this did not significantly enhance overall or disease-free survival.
Supporting Evidence
- Objective response rates improved from 53.1% in the first study to 93.5% in the third study.
- Median disease-free survival was 16.7 months for the first study and 22.4 months for the third study.
- Overall survival rates did not show significant improvement despite better response rates.
Takeaway
Doctors treated 178 women with a serious type of breast cancer using a mix of chemotherapy and surgery, and found that while the treatments worked better over time, they didn't make a big difference in how long the women lived without the cancer coming back.
Methodology
Patients received neoadjuvant chemotherapy followed by either surgery or radiotherapy, with follow-up assessments for response and survival.
Potential Biases
Potential bias due to non-randomized treatment choices and historical controls.
Limitations
The study is not randomized and relies on historical comparisons, which may introduce bias.
Participant Demographics
178 patients with non-metastatic inflammatory breast cancer, average age at diagnosis around 49 years.
Statistical Information
P-Value
0.15
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website